These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
444 related items for PubMed ID: 8989999
21. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Bramson JL, Hitt M, Gauldie J, Graham FL. Gene Ther; 1997 Oct; 4(10):1069-76. PubMed ID: 9415313 [Abstract] [Full Text] [Related]
22. New serotypes of adenoviral vectors. Stone D, Lieber A. Curr Opin Mol Ther; 2006 Oct; 8(5):423-31. PubMed ID: 17078384 [Abstract] [Full Text] [Related]
23. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J. J Immunol; 2004 May 15; 172(10):6290-7. PubMed ID: 15128818 [Abstract] [Full Text] [Related]
24. Increased duration of transgene expression in the lung with plasmid DNA vectors harboring adenovirus E4 open reading frame 3. Yew NS, Marshall J, Przybylska M, Wysokenski DM, Ziegler RJ, Rafter PW, Li C, Armentano D, Cheng SH. Hum Gene Ther; 1999 Jul 20; 10(11):1833-43. PubMed ID: 10446923 [Abstract] [Full Text] [Related]
25. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Juillard V, Villefroy P, Godfrin D, Pavirani A, Venet A, Guillet JG. Eur J Immunol; 1995 Dec 20; 25(12):3467-73. PubMed ID: 8566039 [Abstract] [Full Text] [Related]
27. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Scaria A, St George JA, Gregory RJ, Noelle RJ, Wadsworth SC, Smith AE, Kaplan JM. Gene Ther; 1997 Jun 20; 4(6):611-7. PubMed ID: 9231078 [Abstract] [Full Text] [Related]
28. Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression. Cao H, Yang T, Li XF, Wu J, Duan C, Coates AL, Hu J. Gene Ther; 2011 Feb 20; 18(2):173-81. PubMed ID: 20882053 [Abstract] [Full Text] [Related]
29. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Poller W, Schneider-Rasp S, Liebert U, Merklein F, Thalheimer P, Haack A, Schwaab R, Schmitt C, Brackmann HH. Gene Ther; 1996 Jun 20; 3(6):521-30. PubMed ID: 8789802 [Abstract] [Full Text] [Related]
40. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Ilan Y, Sauter B, Chowdhury NR, Reddy BV, Thummala NR, Droguett G, Davidson A, Ott M, Horwitz MS, Chowdhury JR. Hepatology; 1998 May 20; 27(5):1368-76. PubMed ID: 9581693 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]